Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective
Andrea Carta, Maria Del Zompo, Anna Meloni, Francesco Mola, Pasquale Paribello, Federica Pinna, Marco Pinna, Claudia Pisanu, Mirko Manchia, Alessio Squassina, Bernardo Carpiniello, Claudio Conversano
Plonger dans les sujets de recherche 'Cost–Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective'. Ensemble, ils forment une empreinte numérique unique.